^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Gazyva (obinutuzumab)

    i
    Other names: RG 7159, RG7159, RO5072759, GA-101, R-7159, RG-7159, RO-5072759, GA101, R 7159, RO 5072759, GA 101, R7159
    Company:
    Biogen, Nippon Shinyaku, Roche
    Drug class:
    CD20 inhibitor
    Related drugs:
    2d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    3d
    NCI-2024-00209: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Jan 2027 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Columvi (glofitamab-gxbm)
    4d
    OSU-14266: Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=87, Active, not recruiting, Kerry Rogers | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • B2M (Beta-2-microglobulin)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    6d
    Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    9d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    11d
    Radio-GLO: Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Olivia Newton-John Cancer Research Institute
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL4 (Interleukin 4)
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    13d
    Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. (PubMed, Cancer Med)
    In real-world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first-line therapy in patients with TP53 wild-type CLL.
    Journal • Real-world evidence • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    17d
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, National Cancer Institute (NCI) | N=55 --> 34 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)
    18d
    HO158: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial) (2022-502808-72-00)
    P1/2, N=85, Active, not recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    18d
    2023/ABM/01/00072: A study aimed at Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) (2024-513917-11-01)
    P1/2, N=36, Not yet recruiting, Uniwersytet Medyczny W Lublinie
    New P1/2 trial
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Darzalex (daratumumab)
    20d
    Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53)
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • Columvi (glofitamab-gxbm)
    21d
    The Clinical Application Study of Obinutuzumab in Pediatric Refractory Nephrotic Syndrome (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Children's Hospital of Chongqing Medical University
    New trial
    |
    Gazyva (obinutuzumab)